Invex Therapeutics Ltd (IXC.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.10 (+0.00%) as of
Key statistics
- Market cap
- 7.52M
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0900 – 0.1500
- Beta
- 0.52
- Revenue (TTM)
- 46.83k
- Profit margin
- 0.00%
- Volume
- 86.75k
About Invex Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Perth, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.